BR112021005668A2 - processo para fabricação de alfa-cetoglutarato de cálcio - Google Patents
processo para fabricação de alfa-cetoglutarato de cálcio Download PDFInfo
- Publication number
- BR112021005668A2 BR112021005668A2 BR112021005668-8A BR112021005668A BR112021005668A2 BR 112021005668 A2 BR112021005668 A2 BR 112021005668A2 BR 112021005668 A BR112021005668 A BR 112021005668A BR 112021005668 A2 BR112021005668 A2 BR 112021005668A2
- Authority
- BR
- Brazil
- Prior art keywords
- alpha
- water
- ketoglutaric acid
- mixture
- weight
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 172
- LADYPAWUSNPKJF-UHFFFAOYSA-L calcium;2-oxopentanedioate Chemical compound [Ca+2].[O-]C(=O)CCC(=O)C([O-])=O LADYPAWUSNPKJF-UHFFFAOYSA-L 0.000 title claims description 97
- 230000008569 process Effects 0.000 title description 8
- 159000000007 calcium salts Chemical class 0.000 claims abstract description 211
- KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical class [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 claims abstract description 113
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 claims description 966
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 533
- 229910001868 water Inorganic materials 0.000 claims description 533
- HWXBTNAVRSUOJR-UHFFFAOYSA-N alpha-hydroxyglutaric acid Natural products OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 claims description 479
- 229940009533 alpha-ketoglutaric acid Drugs 0.000 claims description 479
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical group [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 474
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 404
- 239000000203 mixture Substances 0.000 claims description 368
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 237
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 237
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 202
- 229910052783 alkali metal Inorganic materials 0.000 claims description 88
- -1 alkali metal salt Chemical class 0.000 claims description 79
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 67
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 55
- 239000001110 calcium chloride Substances 0.000 claims description 47
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 47
- 235000011148 calcium chloride Nutrition 0.000 claims description 40
- 150000003839 salts Chemical class 0.000 claims description 39
- 239000002253 acid Substances 0.000 claims description 20
- 239000011575 calcium Substances 0.000 claims description 20
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 17
- 229910052791 calcium Inorganic materials 0.000 claims description 17
- 238000001035 drying Methods 0.000 claims description 16
- 150000001340 alkali metals Chemical class 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 5
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical group [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 5
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims description 5
- 239000001639 calcium acetate Substances 0.000 claims description 5
- 235000011092 calcium acetate Nutrition 0.000 claims description 5
- 229960005147 calcium acetate Drugs 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229910052744 lithium Inorganic materials 0.000 claims description 4
- CBOCVOKPQGJKKJ-UHFFFAOYSA-L Calcium formate Chemical compound [Ca+2].[O-]C=O.[O-]C=O CBOCVOKPQGJKKJ-UHFFFAOYSA-L 0.000 claims description 3
- 229960002713 calcium chloride Drugs 0.000 claims description 3
- 239000004281 calcium formate Substances 0.000 claims description 3
- 229940044172 calcium formate Drugs 0.000 claims description 3
- 235000019255 calcium formate Nutrition 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical class [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- 150000004683 dihydrates Chemical class 0.000 claims description 2
- 159000000001 potassium salts Chemical class 0.000 claims description 2
- VMSLCPKYRPDHLN-UHFFFAOYSA-N (R)-Humulone Chemical compound CC(C)CC(=O)C1=C(O)C(CC=C(C)C)=C(O)C(O)(CC=C(C)C)C1=O VMSLCPKYRPDHLN-UHFFFAOYSA-N 0.000 claims 1
- GWDFZHKLRCFMOK-UHFFFAOYSA-N O.O.[Ca].[Ca] Chemical compound O.O.[Ca].[Ca] GWDFZHKLRCFMOK-UHFFFAOYSA-N 0.000 claims 1
- 235000017550 sodium carbonate Nutrition 0.000 description 192
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 72
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 63
- 239000000243 solution Substances 0.000 description 53
- 238000006243 chemical reaction Methods 0.000 description 44
- 239000012535 impurity Substances 0.000 description 25
- 230000015572 biosynthetic process Effects 0.000 description 23
- 239000002244 precipitate Substances 0.000 description 19
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 18
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 18
- 239000007787 solid Substances 0.000 description 17
- 238000003786 synthesis reaction Methods 0.000 description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 11
- 238000012546 transfer Methods 0.000 description 11
- 239000012086 standard solution Substances 0.000 description 10
- 150000003751 zinc Chemical class 0.000 description 10
- 239000012488 sample solution Substances 0.000 description 9
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 7
- 239000011736 potassium bicarbonate Substances 0.000 description 7
- 235000015497 potassium bicarbonate Nutrition 0.000 description 7
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical group [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 235000011181 potassium carbonates Nutrition 0.000 description 5
- 229910001414 potassium ion Inorganic materials 0.000 description 5
- 229910001415 sodium ion Inorganic materials 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- YBGBJYVHJTVUSL-UHFFFAOYSA-L disodium;2-oxopentanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CCC(=O)C([O-])=O YBGBJYVHJTVUSL-UHFFFAOYSA-L 0.000 description 4
- 235000021472 generally recognized as safe Nutrition 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000012490 blank solution Substances 0.000 description 3
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical group [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 3
- PBUBJNYXWIDFMU-UHFFFAOYSA-L calcium;butanedioate Chemical compound [Ca+2].[O-]C(=O)CCC([O-])=O PBUBJNYXWIDFMU-UHFFFAOYSA-L 0.000 description 3
- SMBQBQBNOXIFSF-UHFFFAOYSA-N dilithium Chemical class [Li][Li] SMBQBQBNOXIFSF-UHFFFAOYSA-N 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 3
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 3
- 229910052808 lithium carbonate Inorganic materials 0.000 description 3
- HQRPHMAXFVUBJX-UHFFFAOYSA-M lithium;hydrogen carbonate Chemical compound [Li+].OC([O-])=O HQRPHMAXFVUBJX-UHFFFAOYSA-M 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 235000005074 zinc chloride Nutrition 0.000 description 3
- 239000011592 zinc chloride Substances 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- VTYGSWGUBDXCRA-UHFFFAOYSA-L dipotassium;2-oxopentanedioate Chemical compound [K+].[K+].[O-]C(=O)CCC(=O)C([O-])=O VTYGSWGUBDXCRA-UHFFFAOYSA-L 0.000 description 2
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical class [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- QNFIHKFBQFJVKV-UHFFFAOYSA-N 5-octoxy-4,5-dioxopentanoic acid Chemical compound CCCCCCCCOC(=O)C(=O)CCC(O)=O QNFIHKFBQFJVKV-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- TXIXSLPEABAEHP-UHFFFAOYSA-N Dimethyl 2-oxoglutarate Chemical compound COC(=O)CCC(=O)C(=O)OC TXIXSLPEABAEHP-UHFFFAOYSA-N 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 238000010268 HPLC based assay Methods 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002715 bioenergetic effect Effects 0.000 description 1
- 238000011095 buffer preparation Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- VWPLIFKKLCVFCQ-UHFFFAOYSA-L calcium;2-oxopentanedioate;hydrate Chemical compound O.[Ca+2].[O-]C(=O)CCC(=O)C([O-])=O VWPLIFKKLCVFCQ-UHFFFAOYSA-L 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229950010286 diolamine Drugs 0.000 description 1
- MYTMXVHNEWBFAL-UHFFFAOYSA-L dipotassium;carbonate;hydrate Chemical compound O.[K+].[K+].[O-]C([O-])=O MYTMXVHNEWBFAL-UHFFFAOYSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960001078 lithium Drugs 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 229940123729 mTOR kinase inhibitor Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005787 mitochondrial ATP synthesis coupled electron transport Effects 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229950004864 olamine Drugs 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- KEAYESYHFKHZAL-OUBTZVSYSA-N sodium-24 Chemical compound [24Na] KEAYESYHFKHZAL-OUBTZVSYSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 235000021139 traditional diet Nutrition 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 231100000402 unacceptable toxicity Toxicity 0.000 description 1
- 238000010977 unit operation Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- IPCXNCATNBAPKW-UHFFFAOYSA-N zinc;hydrate Chemical compound O.[Zn] IPCXNCATNBAPKW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/418—Preparation of metal complexes containing carboxylic acid moieties
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/347—Saturated compounds containing more than one carboxyl group containing keto groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Fodder In General (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862736320P | 2018-09-25 | 2018-09-25 | |
| US62/736,320 | 2018-09-25 | ||
| PCT/US2019/052498 WO2020068705A1 (en) | 2018-09-25 | 2019-09-23 | Process of making calcium alpha-ketoglutarate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021005668A2 true BR112021005668A2 (pt) | 2021-06-22 |
Family
ID=69952136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021005668-8A BR112021005668A2 (pt) | 2018-09-25 | 2019-09-23 | processo para fabricação de alfa-cetoglutarato de cálcio |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11802103B2 (https=) |
| EP (1) | EP3856166A4 (https=) |
| JP (1) | JP7499259B2 (https=) |
| KR (1) | KR102833111B1 (https=) |
| CN (1) | CN112955139B (https=) |
| AU (1) | AU2019350699B2 (https=) |
| BR (1) | BR112021005668A2 (https=) |
| CA (1) | CA3112205A1 (https=) |
| CL (1) | CL2021000728A1 (https=) |
| CO (1) | CO2021004529A2 (https=) |
| IL (1) | IL281761B2 (https=) |
| MX (1) | MX2021003482A (https=) |
| MY (1) | MY203278A (https=) |
| PE (1) | PE20211816A1 (https=) |
| PH (1) | PH12021550403A1 (https=) |
| SG (1) | SG11202102204PA (https=) |
| TW (1) | TWI863930B (https=) |
| WO (1) | WO2020068705A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7499259B2 (ja) | 2018-09-25 | 2024-06-13 | ポンス デ レオン ヘルス デジグネイテッド アクティビティ カンパニー | αケトグルタル酸カルシウムを製造するためのプロセス |
| CN112941116B (zh) * | 2021-01-04 | 2022-12-02 | 上海朴颐化学科技有限公司 | 一种酶法制备α-酮戊二酸钙的方法 |
| CN114105761B (zh) * | 2021-11-19 | 2024-06-21 | 广东派特埃尔生物科技有限公司 | 一种α-酮戊二酸钠盐的合成工艺 |
| CN115974679A (zh) * | 2022-12-20 | 2023-04-18 | 绍兴市精益生物化工有限公司 | α-酮戊二酸钙盐制备方法 |
| CN119977789A (zh) * | 2025-02-12 | 2025-05-13 | 江苏惠利生物科技有限公司 | 一种离子交换树脂制备高纯度α-酮戊二酸钙的方法 |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2776926A (en) | 1955-08-04 | 1957-01-08 | Eugene S Sharpe | Preparation of alpha-ketoglutaric acid by serratia marcescens |
| US2917528A (en) | 1956-08-24 | 1959-12-15 | Victor Chemical Works | Alkanolaminealkanephosphonic acids and salts thereof |
| US2841616A (en) * | 1956-10-30 | 1958-07-01 | Campbell Soup Co | Process for the recovery of alpha-ketoglutaric acid |
| US3875304A (en) | 1970-04-24 | 1975-04-01 | Schlitz Brewing Co J | Livestock feed composition and method of preparing the same |
| US4045585A (en) | 1976-05-19 | 1977-08-30 | Decel Corporation | Flavored animal food compositions |
| DE3151196A1 (de) * | 1981-12-23 | 1983-06-30 | Kurt Heinz Prof. Dr. 7800 Freiburg Bauer | Verfahren zur herstellung von gut loeslichen 5-aminosalicylsaeure-arzneimittelzubereitungen |
| US6451341B1 (en) | 1990-02-05 | 2002-09-17 | Thomas J. Slaga | Time release formulation of vitamins, minerals and other beneficial supplements |
| US5646187A (en) | 1992-05-20 | 1997-07-08 | Ab Erik Vinnars | Use of alpha-ketoglutarate |
| US6306430B1 (en) | 1998-04-16 | 2001-10-23 | The Iams Company | Process for decreasing adiposity using vitamin a as a dietary supplement |
| US6905707B2 (en) | 1998-05-28 | 2005-06-14 | Medical Research Institute | Controlled release arginine alpha ketoglutarate |
| CO5140079A1 (es) | 1998-10-14 | 2002-03-22 | Novartis Ag | Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo |
| US6649654B1 (en) | 1999-11-23 | 2003-11-18 | The Regents Of The University Of California | Methods for identifying and using IKK inhibitors |
| US7169755B2 (en) | 2000-12-20 | 2007-01-30 | Alcon, Inc. | Solution for removing cataracts via liquefracture |
| EP1622629B1 (en) * | 2003-05-07 | 2013-07-10 | Osteologix A/S | Controlled-release composition containing a strontium salt |
| EP1744770A2 (en) * | 2004-05-06 | 2007-01-24 | Osteologix A/S | High yield and rapid syntheses methods for producing metallo-organic salts |
| PL368572A1 (en) * | 2004-06-17 | 2005-12-27 | Sgp & Sons Ab | Pharmaceutical compound for prevention and therapy of increased level of cholesterol, ldl and triglycerides as well as application of the pharmaceutical compound as an agent acting against atherosclerosis and used in circulatory system affections |
| US20090005437A1 (en) | 2004-08-09 | 2009-01-01 | Eyal Gottlieb | Alpha-Ketoglutarates and Their Use as Therapeutic Agents |
| ES2510690T3 (es) | 2004-12-17 | 2014-10-21 | Alan B. Cash | Método para extender la esperanza de vida y retrasar la aparición de enfermedad relacionada con la edad |
| US20060234250A1 (en) | 2005-04-15 | 2006-10-19 | Powers Ralph W Iii | Methods of screening and compositions for life span modulators |
| WO2007001883A2 (en) | 2005-06-20 | 2007-01-04 | Accera, Inc. | Method to reduce oxidative damage and improve mitochondrial efficiency |
| US20070105942A1 (en) | 2005-11-08 | 2007-05-10 | Heuer Marvin A | Supplemental dietary composition for turning on anabolic switches in muscle, stimulating and/or optimizing protein synthesis, and/or potently signaling muscle building and/or growth via molecular pathways |
| US8367121B2 (en) | 2005-11-23 | 2013-02-05 | Florida A & M University | Nutraceutical agent for attenuating the neurodegenerative process associated with Parkinson's disease |
| PL379512A1 (pl) | 2006-04-21 | 2007-10-29 | Sgp & Sons Ab | Nowe metody i ich zastosowanie |
| PL226695B1 (pl) | 2006-07-03 | 2017-08-31 | Danuta Kruszewska | Środek do zastosowania w zapobieganiu i/lub hamowaniu kolonizacji Helicobacter pylori, zastosowanie soli kwasu alfa‑ketoglutarowego z metalami alkalicznymi i ziem alkalicznych do wytwarzania środka leczniczego oraz dodatku do żywności do zapobiegania i/lub hamowania kolonizacji Helicobacter pylori |
| NZ579340A (en) | 2007-03-19 | 2012-05-25 | Metaproteomics Llc | Methods and compositions for promoting bone and joint health comprising berberine |
| EP2173336B1 (en) | 2007-07-02 | 2016-03-30 | Protista Biotechnology AB | Alpha-ketoglutaric acid for use in the treatment of hypertension or pulmonary hypertension |
| EP2033623A1 (en) | 2007-09-07 | 2009-03-11 | Cutech S.R.L. | Compositions comprising ornithine ketoglutarate (OKG) |
| JP5406643B2 (ja) * | 2008-09-22 | 2014-02-05 | 日本合成化学工業株式会社 | α−オキソカルボン酸の金属塩の製造方法 |
| CN101759553A (zh) | 2008-11-21 | 2010-06-30 | 扬子江药业集团北京海燕药业有限公司 | α-酮酸钙的制备方法 |
| DE102009016119A1 (de) | 2009-04-03 | 2010-10-14 | Evonik Degussa Gmbh | Nahrungsergänzungsmittel enthaltend alpha-Ketosäuren zur Unterstützung der Diabetestherapie |
| AU2010233073B2 (en) | 2009-04-10 | 2014-07-31 | Haiyan Qi | Novel anti-aging agents and methods to identify them |
| AU2010247800A1 (en) | 2009-05-11 | 2011-12-15 | Berg Llc | Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers |
| JP2012527894A (ja) | 2009-05-28 | 2012-11-12 | ザ・アイムス・カンパニー | 被覆キブル形態のペットフード |
| AU2010258356B2 (en) | 2009-06-12 | 2017-01-19 | Generex Pharmaceuticals, Inc. | Compositions and methods for prevention and treatment of brain diseases and conditions |
| WO2011000218A1 (en) | 2009-06-30 | 2011-01-06 | Shuen-Lu Huang | Compositions containing berberine or analogs thereof for treating rosacea or red face related skin disorders |
| WO2011060305A1 (en) | 2009-11-12 | 2011-05-19 | Nox Technologies, Inc. | Potato skin compositions that lower cytosolic nadh level to mimic calorie restriction |
| WO2012114204A2 (en) | 2011-02-15 | 2012-08-30 | Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto | Methods of treating mitochondrial dysfunction |
| CN103491804A (zh) | 2011-04-18 | 2014-01-01 | 雀巢产品技术援助有限公司 | 具有α-HICA 和二十碳五烯酸的营养组合物 |
| US9248185B2 (en) | 2011-06-16 | 2016-02-02 | President And Fellows Of Harvard College | Methods of increasing satellite cell proliferation |
| CN102586347B (zh) * | 2012-03-06 | 2014-04-09 | 江南大学 | 一种两阶段pH控制高产a-酮戊二酸的方法 |
| US9532997B2 (en) | 2012-04-03 | 2017-01-03 | Whitehead Institute For Biomedical Research | Compositions and methods for promoting intestinal stem cell function |
| ITBO20120226A1 (it) | 2012-04-24 | 2013-10-25 | Alfa Wassermann Spa | Composizioni comprendenti ornitina alfa-chetoglutarato, processi per il loro ottenimento e il loro uso. |
| JP6029058B2 (ja) * | 2012-09-14 | 2016-11-24 | 国立研究開発法人農業・食品産業技術総合研究機構 | シュウ酸カルシウムを含む氷核活性剤 |
| FI3398594T3 (en) | 2012-09-19 | 2024-09-23 | Grespo Ab | Compositions for improvement of brain function |
| CN102976927A (zh) * | 2012-12-26 | 2013-03-20 | 天津天成制药有限公司 | α-酮戊二酸钙的制备方法 |
| CA2896646A1 (en) | 2012-12-27 | 2014-07-03 | Hayashibara Co., Ltd. | Skin-exterior anti-ageing composition and production method therefor |
| WO2014116985A1 (en) | 2013-01-25 | 2014-07-31 | Winning The Fight Inc. | Composition for treatment of neurodegenerative disease |
| US9511057B2 (en) | 2013-03-15 | 2016-12-06 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treating denervation-induced muscle atrophy |
| CA2902603C (en) | 2013-03-19 | 2021-03-02 | University Of South Florida | Compositions and methods for producing elevated and sustained ketosis |
| US20160263092A1 (en) | 2013-12-19 | 2016-09-15 | Twi Biotechnology, Inc. | Therapeutic uses of berberine formulations |
| CN106163513A (zh) | 2014-02-12 | 2016-11-23 | 加利福尼亚大学董事会 | 用于治疗衰老和与年龄相关的疾病和症状的组合物和方法 |
| WO2015171723A1 (en) | 2014-05-06 | 2015-11-12 | Research Development Foundation | Methods for treating insulin resistance and for sensitizing patients to glp1 agonist therapy |
| CA2953387C (en) | 2014-06-30 | 2023-11-28 | The Regents Of The University Of California | Ketobutyrate compounds and compositions for treating age-related symptoms and diseases |
| CA2945609C (en) | 2014-07-29 | 2023-05-23 | Shenzhen Hightide Biopharmaceutical, Ltd. | Berberine-ursodeoxycholic salt, method of preparation and application therof |
| US20170266253A1 (en) | 2014-07-31 | 2017-09-21 | Indiana University Research And Technology Corporation | Antithetical regulation of endothelial ace and ace2 by brg1-foxm1 complex underlies pathological cardiac hypertrophy |
| CN104529755B (zh) * | 2014-12-29 | 2016-01-06 | 精晶药业股份有限公司 | 一种从转化液中分离α-酮戊二酸的方法 |
| CA2981754A1 (en) | 2015-04-06 | 2016-10-13 | Shenzhen Hightide Biopharmaceutical, Ltd. | Conjugate compounds of ursodeoxycholic, berberine or l-carnitine, and compositions and methods thereof |
| JP2018517774A (ja) | 2015-06-10 | 2018-07-05 | エリジウム・ヘルス・インコーポレイテッド | ニコチンアミドリボシドおよびプテロスチルベン組成物ならびに皮膚障害の処置のための方法 |
| WO2017008060A1 (en) | 2015-07-08 | 2017-01-12 | Unity Biotechnology, Inc. | Compositions and methods for treating senescence-associated diseases and disorders |
| US20190247342A1 (en) | 2016-09-30 | 2019-08-15 | The Regents Of The University Of California | Alpha-Ketobutyrate, 2-Hydroxybutyrate, and Alpha-Ketoglutarate for Stimulating Hair Growth |
| PL231635B1 (pl) * | 2017-01-03 | 2019-03-29 | Politechnika Poznanska | Sposób produkcji kwasu alfa-ketoglutarowego (AKG) z jednoskładnikowych roztworów wodnych |
| MX2017004010A (es) | 2017-03-27 | 2018-02-09 | Antonio Hernandez Miramontes Jorge | Mezcla de oxalacetato, alfacetoglutarato, ácido tartánico y sales de lactato de calcio y sodio, para tratar pacientes con insuficiencia renal crónica. |
| EP3615029A4 (en) | 2017-04-25 | 2021-04-21 | Buck Institute for Research on Aging | FORMULATIONS TO EXTEND LIFE AND HEALTH |
| US20200253907A1 (en) | 2017-08-21 | 2020-08-13 | The Regents Of The University Of California | Compositions and Methods for Treating Neurodegenerative Diseases |
| JP7499259B2 (ja) | 2018-09-25 | 2024-06-13 | ポンス デ レオン ヘルス デジグネイテッド アクティビティ カンパニー | αケトグルタル酸カルシウムを製造するためのプロセス |
| WO2020086733A1 (en) | 2018-10-24 | 2020-04-30 | Ponce De Leon Health Designated Activity Company | Nicotinamide riboside compositions for healthspan extension |
| JP2022536653A (ja) | 2019-06-10 | 2022-08-18 | バック インスティチュート フォー リサーチ オン エージング | 老化関連分泌表現型を修整する方法および組成物 |
| DK3980001T3 (da) * | 2019-06-10 | 2025-12-01 | Ponce De Leon Health Designated Activity Company | Depotsammensætninger af alfa-ketoglutarat |
| CA3188646A1 (en) | 2020-07-02 | 2022-01-06 | Ponce De Leon Health Designated Activity Company | Compositions and methods for treating crp-mediated diseases |
| CN112941116B (zh) * | 2021-01-04 | 2022-12-02 | 上海朴颐化学科技有限公司 | 一种酶法制备α-酮戊二酸钙的方法 |
| CN115974679A (zh) * | 2022-12-20 | 2023-04-18 | 绍兴市精益生物化工有限公司 | α-酮戊二酸钙盐制备方法 |
-
2019
- 2019-09-23 JP JP2021540377A patent/JP7499259B2/ja active Active
- 2019-09-23 SG SG11202102204PA patent/SG11202102204PA/en unknown
- 2019-09-23 US US17/277,752 patent/US11802103B2/en active Active
- 2019-09-23 KR KR1020217010402A patent/KR102833111B1/ko active Active
- 2019-09-23 PE PE2021000354A patent/PE20211816A1/es unknown
- 2019-09-23 EP EP19866432.8A patent/EP3856166A4/en active Pending
- 2019-09-23 WO PCT/US2019/052498 patent/WO2020068705A1/en not_active Ceased
- 2019-09-23 IL IL281761A patent/IL281761B2/en unknown
- 2019-09-23 CA CA3112205A patent/CA3112205A1/en active Pending
- 2019-09-23 AU AU2019350699A patent/AU2019350699B2/en active Active
- 2019-09-23 BR BR112021005668-8A patent/BR112021005668A2/pt unknown
- 2019-09-23 CN CN201980073655.2A patent/CN112955139B/zh active Active
- 2019-09-23 MY MYPI2021001576A patent/MY203278A/en unknown
- 2019-09-23 MX MX2021003482A patent/MX2021003482A/es unknown
- 2019-09-25 TW TW108134655A patent/TWI863930B/zh active
-
2021
- 2021-02-26 PH PH12021550403A patent/PH12021550403A1/en unknown
- 2021-03-24 CL CL2021000728A patent/CL2021000728A1/es unknown
- 2021-04-11 CO CONC2021/0004529A patent/CO2021004529A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US11802103B2 (en) | 2023-10-31 |
| US20210371368A1 (en) | 2021-12-02 |
| KR102833111B1 (ko) | 2025-07-10 |
| JP7499259B2 (ja) | 2024-06-13 |
| IL281761B1 (en) | 2025-05-01 |
| PE20211816A1 (es) | 2021-09-14 |
| CO2021004529A2 (es) | 2021-04-30 |
| TWI863930B (zh) | 2024-12-01 |
| SG11202102204PA (en) | 2021-04-29 |
| WO2020068705A1 (en) | 2020-04-02 |
| JP2022502489A (ja) | 2022-01-11 |
| CN112955139B (zh) | 2025-04-18 |
| EP3856166A1 (en) | 2021-08-04 |
| KR20210065120A (ko) | 2021-06-03 |
| EP3856166A4 (en) | 2022-06-22 |
| MY203278A (en) | 2024-06-21 |
| PH12021550403A1 (en) | 2021-10-04 |
| CL2021000728A1 (es) | 2021-10-22 |
| MX2021003482A (es) | 2021-06-18 |
| TW202024013A (zh) | 2020-07-01 |
| IL281761A (en) | 2021-05-31 |
| AU2019350699B2 (en) | 2024-05-23 |
| AU2019350699A1 (en) | 2021-04-08 |
| IL281761B2 (en) | 2025-09-01 |
| CN112955139A (zh) | 2021-06-11 |
| CA3112205A1 (en) | 2020-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021005668A2 (pt) | processo para fabricação de alfa-cetoglutarato de cálcio | |
| Plimmer | Esters of phosphoric acid: Phosphoryl hydroxyamino-acids | |
| KR102697726B1 (ko) | 설카딘 염 | |
| JP4177471B2 (ja) | 混合グルコサミン塩の製造法 | |
| IE64112B1 (en) | New strontium salt process for the preparation thereof and pharmaceutical compositions containing it | |
| JPS5827263B2 (ja) | Ｎ−アシル−αおよびβ−アスパルチルグルタミン酸塩の製造方法 | |
| JPH0696556B2 (ja) | ２−キノロン誘導体 | |
| US3064038A (en) | Process for preparing sodium acetylsalicylate | |
| US3907869A (en) | Method of producing calcium pangamate | |
| JP3637019B2 (ja) | 新規な結晶性パミドロン酸二ナトリウム水和物及びその製造方法 | |
| US3397212A (en) | Eucalyptol derivatives | |
| JP2018104312A (ja) | イミダゾピロロキノリン塩及びその製造方法、並びに、医薬品、化粧品及び食品 | |
| JPS6281365A (ja) | グアニジノエタンチオスルホン酸、その製造法、及びそれを含有するコレステロ−ル低下剤 | |
| US3644395A (en) | Phenylbutazone-sodium-monoglycerate | |
| RU2756322C1 (ru) | Способ получения аморфных водорастворимых солей цитрата магния | |
| CN110240623A (zh) | 可降低3＇,5＇-环化腺苷酸中无机盐杂质的结晶方法 | |
| HK40053335B (zh) | 用於制备α-酮戊二酸钙的方法 | |
| Dyson | Organic antimonials of therapeutic activity | |
| US5011974A (en) | Process for the preparation of derivative of 2-diethylamino-1-methylethyl-1-hydroxy-(bicyclohexyl)-2-carboxylate | |
| US3465034A (en) | Adamantane-1-carboxylic acid derivatives | |
| SU1512929A1 (ru) | Способ получени гидрогенфосфата кальци | |
| HK40053335A (en) | Process of making calcium alpha-ketoglutarate | |
| US3043865A (en) | Process for resolving a cyclic hydroxy acid | |
| HK40079384A (en) | Sulcardine salts | |
| RU2603137C1 (ru) | Сульфат 5-гидрокси-1н-имидазол-4-карбоксамида |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |